Effects of prior treatment with salmeterol and formoterol on airway and systemic β2 responses to fenoterol

Thorax

Volumn 51, Issue 6, 1996, Pages 585-589

  Grove, Alison ^a   Lipworth, Brian J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Asthma; Bronchodilation; Fenoterol; Formoterol; Partial agonist; Salmeterol

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; DRUG DERIVATIVE; ETHANOLAMINE DERIVATIVE; FENOTEROL; FORMOTEROL; SALBUTAMOL; SALMETEROL;

ADULT; ARTICLE; ASTHMA; BREATHING MECHANICS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG INTERACTION; FEMALE; HUMAN; MALE; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; ASTHMA; BRONCHODILATOR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ETHANOLAMINES; FEMALE; FENOTEROL; HUMANS; MALE; RESPIRATORY MECHANICS;

EID: 0030162735     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.51.6.585     Document Type: Article

References (17)

1. Ball DI, Brittain RT, Coleman RA, Denyer LH, Jack D, Johnson M, et al. Salmeterol, a novel, long-acting β3adrenoceptor agonist: characterisation of pharmacological activity in vitro and in vivo. Br J Pharniacol 1991;104: 665-71.
2. Linden A, Bergendal A, Ullman A, Skoogh BE, Lofdahl CG. Salmeterol, formoterol, and salbutamol in the isolated guinea-pig trachea: differences in maximum relaxant effect and potency but not in functional antagonism. Thorax 1993;48:547-53.
3. Anderson GP. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective β-adrenoceptor agonist bronchodilator. Life Sci 1993;52:2145-60.
4. Waller DG. β-adrenoceptor partial agonists: a renaissance in cardiovascular therapy. Br J Clin Pharmacol 1990;30: 157-71.
5. Grove A, McFarlane LC, Lipworth BJ. Expression of the β,-adrenoceptor partial agonist/antagonist activity of salbutamol in states of low and high adrenergic tone. Thorax 1995;50:134-8.
6. Grove A, Lipworth BJ. Evaluation of the β2-adrenoceptor agonist/antagonist activity of formoterol and salmeterol. Thorax 1996;51:54-8.
7. O'Donnell SR, Wanstall JC. Evidence that the efficacy (intrinsic activity) of fenoterol is higher than that of salbutamol on β-adrenoceptors in guinea-pig trachea. Eur J Clin Pharmacol 1989;36:239-45.
8. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease and asthma. Am Rev Respir Dis 1987;136:225-44.
9. American Thoracic Society. Standardisation of spirometry - 1987 update. Am Rev Respir Dis 1987;136:1285-98.
10. Lipworth BJ, McDevitt DG. Beta-adrenoceptor responses to salbutamol in normal subjects. Eur J Clin Pharmacol 1989;36:239-45.
11. Grove A, Lipworth BJ. Bronchodilator subsensitivity to inhaled salbutamol after regular twice daily treatment with salmeterol in asthmatic patients. Lancer 1995;346:201-6.
12. Kallstrom BL, Sjoberg J, Waldeck B. The interaction between salmeterol and β,-adrenoceptor agonists with higher efficacy on guinea-pig trachea and human bronchus in vitro. Br} Pharmacol 1994;113:687-92.
13. Smyth ET, Pavord ID, Wong CS, Wisniewski AFZ, Williams J, Tattersfield AE. Interaction and dose-equivalence of salbutamol and salmeterol in patients with asthma. BMJ 1993;306:543-5.
14. Derom EY, Pauwels RA. Time course of bronchodilating effect of inhaled formoterol, a potent and long-acting sympathomimetic. Thorax 1992;47:30-3.
15. Ullman A, Svedmyr N. Salmeterol, a new long-acting inhaled βi-adrenoceptor agonist: comparison with salbutamol in asthmatic patients. Thorax 1988;43:674-8.
16. Naline E, Zhang Y, Qian Y, Marion N, Anderson GP, Grandordy B, et al. Relaxant effects and durations of action of formoterol and salmeterol on the isolated human bronchus. Eur Respir J 1994;7:914-20.
17. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993:306:1034-7.